Evidence map›Paper›PMID 37316165›Full record

ArticleHeart (British Cardiac Society)2023

Cost-effectiveness of a telemonitoring programme in patients with cardiovascular diseases compared with standard of care.

Andreas Ziegler, Alper Öner, Gisela Quadflieg, Raphael O Betschart, Alexandre Thiéry, Hugo Babel, Henry G Mwambi, Henriette Neumeyer, Steffen Mackschin, Sissy Hintz and 3 more

Abstract read
In one paragraph

Article in Heart (British Cardiac Society), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Implantable cardiac monitor in heart failure: just a toy or a useful tool?European heart journal supplements : journal of the European Society of Cardiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Andreas ZieglerCardio-CARE, Davos Wolfgang, Switzerland ziegler.lit@mailbox.org.ORCID 0000-0002-8386-5397
Alper ÖnerDepartment of Cardiology, Center for Internal Medicine, Universitätsmedizin Rostock, Rostock, Germany.ORCID 0000-0001-6116-7021
Gisela QuadfliegPhilips GmbH Market DACH, Hamburg, Germany.ORCID 0000-0003-4056-0494
Raphael O BetschartCardio-CARE, Davos Wolfgang, Switzerland.ORCID 0000-0002-0582-3861
Alexandre ThiéryCardio-CARE, Davos Wolfgang, Switzerland.
Hugo BabelCardio-CARE, Davos Wolfgang, Switzerland.ORCID 0000-0001-5847-379X
Henry G MwambiCardio-CARE, Davos Wolfgang, Switzerland.ORCID 0000-0001-9654-400X
Henriette NeumeyerPhilips GmbH Market DACH, Hamburg, Germany.
Steffen MackschinPhilips GmbH Market DACH, Hamburg, Germany.
Sissy HintzDepartment of Cardiology, Center for Internal Medicine, Universitätsmedizin Rostock, Rostock, Germany.
Miriam MannDepartment of Cardiology, Center for Internal Medicine, Universitätsmedizin Rostock, Rostock, Germany.
Hermann DittrichDepartment of Cardiology, Center for Internal Medicine, Universitätsmedizin Rostock, Rostock, Germany.ORCID 0000-0002-5614-2505
Christian SchmidtDepartment of Cardiology, Center for Internal Medicine, Universitätsmedizin Rostock, Rostock, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe main aim of this work was to analyse the cost-effectiveness of an integrated care concept (NICC) that combines telemonitoring with the support of a care centre in addition to guideline therapy for patients. Secondary aims were to compare health utility and health-related quality of life (QoL) between NICC and standard of care (SoC).

methodsThe randomised controlled CardioCare MV Trial compared NICC and SoC in patients from Mecklenburg-West Pomerania (Germany) with atrial fibrillation, heart failure or treatment-resistant hypertension. QoL was measured using the EQ-5D-5L at baseline, 6 months and 1 year follow-up. Quality-adjusted life years (QALYs), EQ5D utility scores, Visual Analogue Scale (VAS) Scores and VAS adjusted life years (VAS-AL) were calculated. Cost data were obtained from health insurance companies, and the payer perspective was taken in health economic analyses. Quantile regression was used with adjustments for stratification variables.

resultsThe net benefit of NICC (QALY) was 0.031 (95% CI 0.012 to 0.050; p=0.001) in this trial involving 957 patients. EQ5D Index values, VAS-ALs and VAS were larger for NICC compared with SoC at 1 year follow-up (all p≤0.004). Direct cost per patient and year were €323 (CI €157 to €489) lower in the NICC group. When 2000 patients are served by the care centre, NICC is cost-effective if one is willing to pay €10 652 per QALY per year.

conclusionNICC was associated with higher QoL and health utility. The programme is cost-effective if one is willing to pay approximately €11 000 per QALY per year.

Indexed as

Cardiovascular DiseasesHypertensionCost-Benefit AnalysisHumansQuality-Adjusted Life YearsQuality of LifeStandard of CareHealth Care Economics and OrganizationsHeart failureHypertensionTelemedicine

Identifiers

PMID37316165
PMCPMC10579463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.